Skip to main content
SpringerLink
Log in

Retroviral transduction of interferon-γ cDNA into a nonimmunogenic murinefibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor

  • Original Articles
  • Draining Lymph Nodes, T Cells, Gene Modification, Immunotherapy, Interferon γ
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Gene modification of tumor cells with the cDNA for interferon γ (IFNγ) has been shown to increase the immunogenicity of some tumor cells. In order to explore further the possible therapeutic relevance of these previous findings, two clones of the nonimmunogenic MCA-102 fibrosarcoma of C57BL/6 origin were retrovirally transduced with the cDNA encoding murine IFNγ: 102.4JK (4JK), a clone with relatively high major histocompatibility complex (MHC) class I expression, and 102.24JK (24JK), a clone with low expression of surface MHC class I molecules. Retroviral transduction of tumor cells with the cDNA encoding for IFNγ resulted in a substantial up-regulation of MHC class I surface expression in the 24JK clone but little change of class I in the 4JK clone. In an attempt to generate antitumor lymphocytes, these gene-modified cells were inoculated into mouse footpads and draining lymph nodes (DLN) were removed, dispersed, and cultured in vitro for 10 days with irradiated tumor cells and interleukin-2. DLN from mice bearing either unmodified tumor or tumor transduced with cDNA encoding neomycin resistance (Neo R) or IFNγ, were used to treat recipients harboring 3-day pulmonary metastases induced by the parental, unmodified tumor. Treatment with DLN cells obtained following the injection of 24JK tumor cells modified with the gene for IFNγ significantly reduced the number of pulmonary metastases in four separate experiments, compared to groups treated by DLN cells generated from inoculation of either the unmodified, parental 24JK clone or the same clone transduced with theNeo R gene only. In contrast, DLN cells induced either by IFNγ-transduced 4JK (high expression of MHC class I) or an unmodified 4JK tumor (moderate expression of MHC class I) had significant but equal therapeutic efficacy. Although the in vitro growth rate of tumor cell lines was unaffected by the insertion of the mouse IFNγ cDNA, their in vivo (s.c.) growth rates were significantly slower than those of the nontransduced tumors. Thus, after retroviral transduction of the murine IFNγ cDNA into a nonimmunogenic tumor with a very low level of surface expression of MHC class I, modified tumor cells could elicit therapeutic T cells from DLN capable of successfully treating established pulmonary metastases upon adoptive transfer. This strategy significantly confirms previous observations on the potential therapeutic effects of gene modification of tumor cells with IFNγ and extends the realm of therapeutic possibilities to include the use of DLN cells for the development of T-cell based immunotherapies against nonimmunogenic human tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bahram S, Arnold D, Bresnahan M, Strominger JL, Spies T (1991) Two putative subunits of a peptide pump encoded in the human major histocompatibility complex class II region. Proc Natl Acad Sci USA 88: 10094

    PubMed  Google Scholar 

  2. Brown MC, Driscoll J, Monaco JJ (1991) Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes. Nature 353: 355

    PubMed  Google Scholar 

  3. Bruggen P van der, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643

    PubMed  Google Scholar 

  4. Carlow DA, Kerbel RS, Elliot BE (1989) Failure of expression of class I major histocompatibility antigens to alter tumor immunogenicity of a spontaneous murine carcinoma. J Natl Cancer Inst 81: 759

    PubMed  Google Scholar 

  5. Christinck RE, Luscher MA, Barber BH, Williams DB (1991) Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 352: 67

    PubMed  Google Scholar 

  6. Deverson EV, Gow IR, Coadwell WJ, Monaco JJ, Butcher GW, Howard JC (1990) MHC class II region encoding proteins related to the multidrug resistance family of trans-membrane transporters. Nature 348: 738

    PubMed  Google Scholar 

  7. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA (1986) Induction by IL-1 and interferon-γ, tissue distribution, biochemistry and function of a natural adherence molecule (ICAM-1). J Immunol 137: 245

    PubMed  Google Scholar 

  8. Dustin ML, Singer KH, Tuck DT, Springer TA (1988) Adhesions of T lymphoblasts to epidermal keratinocytes is regulated by interferongamma and is mediated by intra-cellular adhesions molecule 1 (ICAM-1). J Exp Med 167: 1323

    PubMed  Google Scholar 

  9. Elliot BE, Carlow DA, Rodricks A, Wade A (1989) Perspectives on the role of MHC antigens in normal and malignant cell development. Adv Cancer Res 53: 181

    PubMed  Google Scholar 

  10. Fox BA, Spiess PJ, Kasid A, Puri R, Mulé JJ, Weber JS, Rosenberg SA (1990) In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes. J Biol Response Mod 9: 499

    PubMed  Google Scholar 

  11. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E (1990) Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Research 50: 7820

    PubMed  Google Scholar 

  12. Glynne R, Powis SH, Bech S, Kelly A, Kerr L-A, Trowsdale J (1991) A proteasome-related gene between the two ABC transporter loci in the class II region of the human MHC. Nature 353: 357

    PubMed  Google Scholar 

  13. Goldberg AL, Rock KL (1992) Proteolysis, proteasomes and antigen presentation. Nature 357: 375

    PubMed  Google Scholar 

  14. Greenberg PD (1991) Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49: 281

    PubMed  Google Scholar 

  15. Hui K, Grosveld F, Festenstein H (1984) Rejection of transplantable AKR leukemia cells following MHC DNA-mediated cell transformation. Nature 311: 750

    PubMed  Google Scholar 

  16. Kruskel WH, Wallis WA (1952) Use of ranks in one-criterion variance analysis. J Am Statist Assoc 47: 583

    Google Scholar 

  17. LeGrue S, Ananthaswamy H, Simeik J (1989) Afferent and efferent specificity in the induction and elicitation of parental cross-protective immunity by an immunogenic murine tumor variant: associative recognition of a unique tumor-specific antigen on somatic cell hybrids. Cancer Res 49: 4747

    PubMed  Google Scholar 

  18. Miller AD, Rosman GJ (1989) Improved retroviral vectors for gene transfer and expression. Biotechniques 7: 980

    PubMed  Google Scholar 

  19. Monaco JJ, Cho S, Attaya M (1990) Transport protein genes in the murine MHC: possible implications for antigen processing. Nature 250: 1723

    Google Scholar 

  20. Mulé JJ, Shu S, Schwarz SL, Rosenberg SA (1984) Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225: 1487

    PubMed  Google Scholar 

  21. Mulé JJ, Yang JC, Lafreniere R, Shu S, Rosenberg SA (1987) Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. J Immunol 139: 285

    PubMed  Google Scholar 

  22. Powis SJ, Deverson EV, Coadwell WJ, Ciruela A, Huskisson NS, Smith H, Butcher GW, Howard JC (1992) Effect of polymorphism of an MHC-linked transporter on the peptides assembled in a class I molecule. Nature 357: 211

    PubMed  Google Scholar 

  23. Restifo NP (1992) Antigen processing and presentation: an update. In DeVita VT Jr, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer updates, vol 2. Lippincott, Philadelphia, p 1

    Google Scholar 

  24. Restifo NP, Esquivel F, Asher AL, Stotter H, Barth RJ, Bennink JR, Mulé JJ, Yewdell JW, Rosenberg SA (1991) Defective presentation of endogenous antigens by a murine sarcoma: implications for the failure of an antitumor immune response. J Immunol 147: 1453

    PubMed  Google Scholar 

  25. Restifo NP, Spiess PJ, Karp SE, Mulé JJ, Rosenberg SA (1992) A nonimmunogenic sarcoma transduced with the cDNA for interferongamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med 175: 1423

    PubMed  Google Scholar 

  26. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mulé JJ, Rosenberg SA, Bennink JR (1993) Identification of human cancers deficient in antigen processing. J Exp Med 177: 265

    PubMed  Google Scholar 

  27. Rosenberg SA, Packard BS, Aebersold PM, Dolomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319: 1676

    PubMed  Google Scholar 

  28. Schreiber H, Ward PL, Rowley DA, Stauss HJ (1988) Unique tumor-specific antigens. Annu Rev Immunol 6: 465

    PubMed  Google Scholar 

  29. Shu SY, Chou T, Sakai K (1989) Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J Immunol 143: 740

    PubMed  Google Scholar 

  30. Spies T, Bresnahan M, Bahram S, Arnold D, Blanck G, Mellins E, Pious D, DeMars R (1990) A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature 348: 744

    PubMed  Google Scholar 

  31. Tanaka K, Isselbacher KJ, Khoury G, Jay G (1985) Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science 228: 26

    PubMed  Google Scholar 

  32. Tanaka K, Hayashi H, Hamada C, Khoury G, Jay G (1986) Expression of major histocompatability complex class I antigens as a strategy for the potentiation of the immune recognition of tumor cells. Proc Natl Acad Sci USA 83: 8723

    PubMed  Google Scholar 

  33. Trowsdale J, Hanson I, Mockridge I, Beck S, Townsend A, Kelly A (1990) Sequences encoded in the class II region of the MHC related to the ‘ABC’ superfamily of transporters. Nature 348: 741

    PubMed  Google Scholar 

  34. Van den Eynde B, Lethé B, Van Pel A, De Plaen E, Boon T (1991) The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 173: 1373

    PubMed  Google Scholar 

  35. Wallich W, Bulbuc N, Hämmerling GJ, Katzav S, Segal S, Feldman M (1985) Abrogation of metastatic properties of tumor cells by de novo expression of H-2 K antigens following H-2 gene transfection. Nature 315: 301

    PubMed  Google Scholar 

  36. Wantanabe Y, Kuribayashi K, Miyatake S, Nishihara K, Nakayama E-I, Taniyama T, Sakata T-A (1989) Exogenous expression of mouse interferon γ cDNA in mouse neuro-blastoma C1300 cells results in reduced tumorigenicity by aumented anti-tumor immunity. Proc Natl Acad Sci USA 86: 9456

    PubMed  Google Scholar 

  37. Weber JS, Rosenberg SA (1988) Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res 48: 5818

    PubMed  Google Scholar 

  38. Weber JS, Jay G, Tanaka K, Rosenberg SA (1987) Immunotherapy of a murine tumor with interleukin-2: increased sensitivity after MHC class I gene transfection. J Exp Med 166: 1716

    PubMed  Google Scholar 

  39. Weis JH, Seidman (1985) The expression of major histo-compatibility antigens under metallothionein gene promoter control. J Immunol 134: 1999

    PubMed  Google Scholar 

  40. Yewdell JW, Bennink JR (1992) Cell biology of antigen processing and presentation to MHC class I molecule-restricted T lymphocytes. Annu Rev Immunol 52: 1

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgery Branch, National Cancer Institute, Division of Cancer Treatment, National Institutes of Health, Bldg. 10, Rm. 2B42, 20892, Bethesda, Maryland, USA

    Eitan Shiloni, Stephen E. Karp, Mary C. Custer, Joel Shilyansky, Nicholas P. Restifo, Steven A. Rosenberg & James J. Mulé

Authors
  1. Eitan Shiloni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen E. Karp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mary C. Custer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joel Shilyansky
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nicholas P. Restifo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Steven A. Rosenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. James J. Mulé
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shiloni, E., Karp, S.E., Custer, M.C. et al. Retroviral transduction of interferon-γ cDNA into a nonimmunogenic murinefibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor. Cancer Immunol Immunother 37, 286–292 (1993). https://doi.org/10.1007/BF01518450

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01518450

Key words

Search

Navigation